Jul 31, 2023 / 08:30PM GMT
Operator
Hello, and welcome to Annexon's conference call. (Operator Instructions) Please be advised this call is being recorded at Annexon's request. I'd now like to turn the call over to Jen Lowe, Chief Financial Officer. You may begin.
Jen Lew - Annexon, Inc. - EVP & CFO
Thank you, and good afternoon. Yesterday, we issued a press release outlining results from our ARCHER Phase 2 clinical trial evaluating ANX007 in patients with geographic atrophy that were presented during an oral presentation at the ASRS 2023 Annual Meeting.
The press release, podium presentations and slides used for this conference call are available under the Events and Presentations page within the Investor section of our website.
Today's discussion will include forward-looking statements related to Annexon's current plans and expectations, which are subject to certain risks and uncertainties.
Actual results may differ materially due to various important factors, including those described in the Risk Factors section of our most recent Form 10Q and other SEC filings.
Annexon Inc ARCHER Phase 2 Results at ASRS Call Transcript
Aug 01, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers